A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan
A phase 3 trial of Datopotamab deruxtecan, Osimertinib, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Overview
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06417814 by AstraZeneca, with 744 participants planned, started 2024-10-04 and due to reach its primary completion in 2026-09-30. Interventions recorded: Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin. Conditions listed: Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Osimertinib, Pemetrexed, Cisplatin, AstraZeneca.
- TrialA Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C
Shares Datopotamab deruxtecan, Pemetrexed, Cisplatin, AstraZeneca.
- TrialPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L
Shares Datopotamab deruxtecan, Osimertinib, AstraZeneca, Small-cell lung cancer.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Datopotamab deruxtecan, Pemetrexed, Cisplatin, AstraZeneca.
- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Osimertinib, Pemetrexed, Cisplatin, AstraZeneca.
- TrialDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Shares Datopotamab deruxtecan, Pemetrexed, Cisplatin, Carboplatin.
- TrialTo Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Shares Osimertinib, Pemetrexed, Cisplatin, AstraZeneca.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Pemetrexed, Cisplatin, AstraZeneca, Carboplatin.